ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 7.370-7.640 for the period, compared to the consensus EPS estimate of 6.730. The company issued revenue guidance of $854.0 million-$873.0 million, compared to the consensus revenue estimate of $847.1 million.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $90.43 on Friday. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -117.44 and a beta of 0.54. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. The business has a fifty day simple moving average of $93.58 and a 200 day simple moving average of $77.54. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same quarter in the previous year, the firm posted $1.34 EPS. The business’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. HC Wainwright raised their target price on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Weiss Ratings raised ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 24th. Finally, Truist Financial increased their price objective on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $99.14.

Insider Buying and Selling

In related news, Director Matthew J. Leonard sold 2,528 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the sale, the director directly owned 6,864 shares in the company, valued at $622,015.68. This trade represents a 26.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Antonio R. Pera sold 7,292 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $94.94, for a total transaction of $692,302.48. Following the transaction, the director owned 22,660 shares in the company, valued at approximately $2,151,340.40. The trade was a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 413,830 shares of company stock worth $36,505,378. 12.70% of the stock is currently owned by company insiders.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP raised its position in shares of ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after acquiring an additional 200,998 shares during the last quarter. First Trust Advisors LP grew its stake in shares of ANI Pharmaceuticals by 128.1% during the second quarter. First Trust Advisors LP now owns 81,214 shares of the specialty pharmaceutical company’s stock worth $5,299,000 after purchasing an additional 45,613 shares during the period. PDT Partners LLC bought a new stake in ANI Pharmaceuticals in the second quarter valued at about $2,965,000. Bank of America Corp DE increased its holdings in ANI Pharmaceuticals by 32.0% in the second quarter. Bank of America Corp DE now owns 185,465 shares of the specialty pharmaceutical company’s stock valued at $12,102,000 after purchasing an additional 44,916 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in ANI Pharmaceuticals by 113.4% in the second quarter. Qube Research & Technologies Ltd now owns 76,185 shares of the specialty pharmaceutical company’s stock valued at $4,971,000 after buying an additional 40,481 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.